We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Two-Thirds of Clinical Trial Subjects for Drugs Approvals Are Outside the U.S., CDER Says
Two-Thirds of Clinical Trial Subjects for Drugs Approvals Are Outside the U.S., CDER Says
Almost two-thirds of participants in clinical trials to support U.S. drug approvals from 2015 to 2019 were outside the U.S., the FDA’s Center for Drug Evaluation and Research (CDER) said in a new report unveiled yesterday.